Sucampo Reports Conclusion of Arbitration Hearing
Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) announced that the hearing on the Company's claims in the demand for arbitration under the applicable provisions of the Collaboration and License Agreement with Takeda Pharmaceuticals Company Limited, or Takeda, dated October 29, 2004, have concluded within the expected timeframe and we look forward to the arbitrators' decision in the first quarter of 2012.
Under the current agreement, Sucampo and Takeda jointly commercialize AMITIZA® (lubiprostone) in the United States for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) and are developing AMITIZA for other gastrointestinal indications.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.